Late-stage intervention with MEK1/2 inhibition improves survival of KPC KrasG12D/fl mice. A, Experimental schematic. KPC KrasG12D/+ and KPC KrasG12D/fl mice were palpated for tumor burden, with palpable tumor burden confirmed by ultrasound imaging, with mice treated continuously from the following day with either vehicle or AZD6244. Tumor growth was monitored by ultrasound imaging once weekly to clinical endpoint. B, Relative volume of pancreatic tumors arising in KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor and aged to clinical endpoint. Tumor volume was measured once weekly by high-resolution ultrasound imaging. Each line represents an individual mouse of the indicated genotype and treatment. KPC KrasG12D/fl vehicle, n = 6; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 4. FC, fold change. C, Change of tumor volume (mm3) of KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with either vehicle control or AZD6244 from palpable tumor between initial ultrasound measurement and a secondary ultrasound measurement (between 6 and 13 days later). Plot represents Log2(FC) of tumor volume between first and second measurements for the full treatment cohort when more than one imaging session was possible. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 7; KPC KrasG12D/+ vehicle, n = 4; KPC KrasG12D/+ AZD6244, n = 4. D, Kaplan–Meier survival curves for KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged to clinical endpoint. KPC KrasG12D/fl vehicle, n = 5; KPC KrasG12D/fl AZD6244, n = 8; KPC KrasG12D/+ vehicle, n = 6; KPC KrasG12D/+ AZD6244, n = 5. MS, median survival. E, Representative hematoxylin and eosin images of tumors from KPC KrasG12D/+ and KPC KrasG12D/fl mice treated with vehicle or AZD6244, as indicated, from palpable tumor burden and aged until clinical endpoint. Representative of five mice per group. Scale bar, 500 μm. F, Left, volcano plot for differentially expressed genes of KPC KrasG12D/+ tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Right, volcano plot for differentially expressed genes of KPC KrasG12D/fl tumors treated with vehicle or AZD6244 from palpable tumor burden to clinical endpoint. Red, significantly altered genes. G, Schematic representing relative impact of WT Kras deletion upon tumur outgrowth and therapeutic responses from KPC KrasG12D/+ and KrasG12D/fl comparison.